Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation in antigen presentation and cancer immunotherapy.

Immunity - 11 Jan 2022

Sivapalan Lavanya, Anagnostou Valsamo

Abstract excerpt

Human leukocyte antigen (HLA) molecules are critical mediators of anti-tumor immune responses. In this issue of Immunity,Chhibber et al. (2021) challenge previous associations between germline HLA zygosity and immunotherapy outcomes, demonstrating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation
Share to Genetic Variation
Share to Histocompatibility Antigens Class I

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35021056
DOI: 10.1016/j.immuni.2021.12.010
PMCID: PMC9844532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Genetic variation in antigen presentation and cancer immunotherapy.PMID 35021056Read ↗

Immunogenetic Diversity and Cancer Immunotherapy DisparitiesSemantic proximity Read ↗

Characterizing MHC-I Genotype Predictive Power for Oncogenic Mutation Probability in Cancer Patients.Semantic proximity Read ↗

Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.Semantic proximity Read ↗

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapySemantic proximity Read ↗

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 AnalysisSemantic proximity Read ↗

Ensuring equity in the era of HLA-restricted cancer therapeuticsSemantic proximity Read ↗

No evidence that HLA genotype influences the driver mutations that occur in cancer patients.Semantic proximity Read ↗

No evidence that HLA genotype influences the driver mutations that occur in cancer patientsSemantic proximity Read ↗

Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.